{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:38:50Z","timestamp":1790041130972,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.bmcl.2019.126677","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T02:08:19Z","timestamp":1568081299000},"page":"126677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B"],"prefix":"10.1016","volume":"29","author":[{"given":"Anton","family":"Shetnev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8114-8223","authenticated-orcid":false,"given":"Roman","family":"Shlenev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Efimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Ivanovskii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Tarasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An\u00e9l","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus P.","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.bmcl.2019.126677_b0005","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.85.13.4934","article-title":"cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties","volume":"85","author":"Bach","year":"1988","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.bmcl.2019.126677_b0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.neuro.22.1.197","article-title":"Monoamine oxidase: from genes to behavior","volume":"22","author":"Shih","year":"1999","journal-title":"Annu Rev Neurosci."},{"issue":"15","key":"10.1016\/j.bmcl.2019.126677_b0015","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1073\/pnas.0710626105","article-title":"Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates\/inhibitors","volume":"105","author":"Son","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.bmcl.2019.126677_b0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nsb732","article-title":"Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders","volume":"9","author":"Binda","year":"2002","journal-title":"Nat Struct Biol."},{"issue":"4","key":"10.1016\/j.bmcl.2019.126677_b0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat Rev Neurosci."},{"issue":"11","key":"10.1016\/j.bmcl.2019.126677_b0030","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00702-018-1881-5","article-title":"90 years of monoamine oxidase: some progress and some confusion","volume":"125","author":"Tipton","year":"2018","journal-title":"J Neural Transm (Vienna)."},{"issue":"3","key":"10.1016\/j.bmcl.2019.126677_b0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1092852912000594","article-title":"Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression","volume":"17","author":"Lum","year":"2012","journal-title":"CNS Spectr."},{"key":"10.1016\/j.bmcl.2019.126677_b0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000407513","article-title":"(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease","volume":"19","author":"Birkmayer","year":"1983","journal-title":"Mod Probl Pharmacopsychiatry."},{"issue":"11","key":"10.1016\/j.bmcl.2019.126677_b0045","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00702-018-1876-2","article-title":"Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects","volume":"125","author":"Riederer","year":"2018","journal-title":"J Neural Transm."},{"issue":"Suppl 1","key":"10.1016\/j.bmcl.2019.126677_b0050","first-page":"S287","article-title":"Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness","volume":"147","author":"Youdim","year":"2006","journal-title":"Br J Pharmacol."},{"issue":"4","key":"10.1016\/j.bmcl.2019.126677_b0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0197-4580(97)00037-7","article-title":"Age-related increases in brain monoamine oxidase B in living healthy human subjects","volume":"18","author":"Fowler","year":"1997","journal-title":"Neurobiol Aging."},{"issue":"4","key":"10.1016\/j.bmcl.2019.126677_b0060","doi-asserted-by":"crossref","first-page":"H1460","DOI":"10.1152\/ajpheart.00700.2002","article-title":"Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats","volume":"284","author":"Maurel","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"10.1016\/j.bmcl.2019.126677_b0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.yjmcc.2013.12.032","article-title":"Monoamine oxidases as sources of oxidants in the heart","volume":"73","author":"Kaludercic","year":"2014","journal-title":"J Mol Cell Cardiol."},{"key":"10.1016\/j.bmcl.2019.126677_b0070","doi-asserted-by":"crossref","first-page":"4375418","DOI":"10.1155\/2016\/4375418","article-title":"Monoamine oxidase is overactivated in left and right ventricles from ischemic hearts: an intriguing therapeutic target","volume":"2016","author":"Manni","year":"2016","journal-title":"Oxid Med Cell Longev."},{"key":"10.1016\/j.bmcl.2019.126677_b0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.freeradbiomed.2015.06.025","article-title":"Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathy","volume":"87","author":"Umbarkar","year":"2015","journal-title":"Free Radic Biol Med."},{"issue":"11","key":"10.1016\/j.bmcl.2019.126677_b0080","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00432-010-0835-6","article-title":"Targeting monoamine oxidase A in advanced prostate cancer","volume":"136","author":"Flamand","year":"2010","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"10.1016\/j.bmcl.2019.126677_b0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bmcl.2018.11.018","article-title":"Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework","volume":"29","author":"Shetnev","year":"2019","journal-title":"Bioorg Med Chem Lett."},{"issue":"9","key":"10.1016\/j.bmcl.2019.126677_b0090","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1021\/jm950595m","article-title":"Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups","volume":"39","author":"Harfenist","year":"1996","journal-title":"J Med Chem."},{"issue":"2","key":"10.1016\/j.bmcl.2019.126677_b0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.expneurol.2009.11.018","article-title":"The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance","volume":"221","author":"Sonsalla","year":"2010","journal-title":"Exp Neurol."},{"key":"10.1016\/j.bmcl.2019.126677_b0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejmech.2018.11.017","article-title":"Pharmaceutical and medicinal significance of sulfur (S(VI))-Containing motifs for drug discovery: a critical review","volume":"162","author":"Zhao","year":"2019","journal-title":"Eur J Med Chem."},{"issue":"1\u20134","key":"10.1016\/j.bmcl.2019.126677_b0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10426509008042128","article-title":"Sulfonyl derivatives of 2,5-diphenylfurazan","volume":"54","author":"Cremlyn","year":"1990","journal-title":"Phosphorus Sulfur."},{"issue":"1","key":"10.1016\/j.bmcl.2019.126677_b0110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14756366.2018.1443447","article-title":"Iodine-mediated one-pot intramolecular decarboxylation domino reaction for accessing functionalised 2-(1,3,4-oxadiazol-2-yl)anilines with carbonic anhydrase inhibitory action","volume":"33","author":"Angapelly","year":"2018","journal-title":"J Enzyme Inhib Med Chem."},{"issue":"47","key":"10.1016\/j.bmcl.2019.126677_b0115","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.1016\/j.tetlet.2009.08.084","article-title":"A mild, one-pot preparation of 1,3,4-oxadiazoles","volume":"50","author":"Li","year":"2009","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bmcl.2019.126677_b0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejmech.2014.05.039","article-title":"Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII","volume":"82","author":"Slawinski","year":"2014","journal-title":"Eur J Med Chem."},{"issue":"15","key":"10.1016\/j.bmcl.2019.126677_b0125","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1016\/j.bmc.2013.05.010","article-title":"Design and synthesis of N-alkyl-N'-substituted 2,4-dioxo-3,4-dihydropyrimidin-1-diacylhydrazine derivatives as ecdysone receptor agonist","volume":"21","author":"Liu","year":"2013","journal-title":"Bioorg Med Chem."},{"issue":"7","key":"10.1016\/j.bmcl.2019.126677_b0130","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1134\/S1070428015070167","article-title":"New synthesis of 3,5-diaryl-1,2,4-oxadiazoles containing a sulfonyl chloride or sulfonamide group","volume":"51","author":"Agat'ev","year":"2015","journal-title":"Russ J Org Chem+."},{"issue":"7","key":"10.1016\/j.bmcl.2019.126677_b0135","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s11172-016-1518-5","article-title":"2-Halobenzenesulfonyl chlorides in the synthesis of pyrido[2,1-c][1,2,4] benzothiadiazine 5,5-dioxide derivatives","volume":"65","author":"Shlenev","year":"2016","journal-title":"Russ Chem B+."},{"issue":"22","key":"10.1016\/j.bmcl.2019.126677_b0140","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1016\/j.bmc.2005.06.043","article-title":"Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening","volume":"13","author":"Novaroli","year":"2005","journal-title":"Bioorg Med Chem."},{"issue":"23","key":"10.1016\/j.bmcl.2019.126677_b0145","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J Med Chem."},{"issue":"5","key":"10.1016\/j.bmcl.2019.126677_b0150","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cmdc.201500059","article-title":"Indanones as high-potency reversible inhibitors of monoamine oxidase","volume":"10","author":"Mostert","year":"2015","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.bmcl.2019.126677_b0155","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm101359c","article-title":"Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex","volume":"54","author":"Binda","year":"2011","journal-title":"J Med Chem."},{"issue":"16","key":"10.1016\/j.bmcl.2019.126677_b0160","doi-asserted-by":"crossref","first-page":"15761","DOI":"10.1074\/jbc.M500949200","article-title":"Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors","volume":"280","author":"Hubalek","year":"2005","journal-title":"J Biol Chem."},{"issue":"9","key":"10.1016\/j.bmcl.2019.126677_b0165","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1055\/s-0033-1345163","article-title":"The inhibition of monoamine oxidase by esomeprazole","volume":"63","author":"Petzer","year":"2013","journal-title":"Drug Res (Stuttg)."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19306274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19306274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:30:57Z","timestamp":1760772657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19306274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":33,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0960894X19306274"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126677","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.126677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"126677"}}